Bristol-Myers Squibb Company (BMY) is a U.S.-listed pharmaceutical stock, so the central target here is built from individual analyst price targets. Published Street targets span roughly $41 to $82, with the lowest view held by Morgan Stanley (Underweight) and the highest by Piper Sandler (Overweight, raised to $82 from $75 in September 2026). The arithmetic mean of all valid targets is about $66 — only roughly 7% above the current price, below the threshold needed for a meaningful "reach" question.
For that reason, the central target used here is the average of the targets above the current price. Across nine verified above-price targets — including UBS ($80), Barclays and Guggenheim ($75 each), J.P. Morgan ($73), Truist and Citigroup ($70 each), and Bank of America ($66) — the mean works out to approximately $73. This is a calculated figure, not an official published consensus. The dispersion is notable: bullish analysts point to pipeline catalysts and discounted valuation, while cautious analysts such as Cantor Fitzgerald ($53) and Leerink Partners ($59, downgraded to Market Perform) emphasize patent-cliff and pricing risk.
Shares recently traded near $61.48, within a 52-week range of roughly $42.52 to $68.64, giving the company a market value near $126 billion. Reaching $73 implies upside of about 19%, which qualifies as a substantial move. The path would likely require a combination of continued execution from newer medicines and a re-rating of the stock's forward price-to-earnings (P/E) multiple, which has been depressed relative to large-cap pharmaceutical peers. The company's third-quarter 2026 results beat expectations — EPS (earnings per share) of $2.04 versus roughly $1.60 anticipated, with revenue of about $12.97 billion — but the stock still pulled back, reflecting the market's focus on longer-term patent exposure rather than near-term results.
Bristol Myers Squibb's "growth portfolio" — including Opdivo, Reblozyl, Camzyos, Breyanzi, and Cobenfy — now represents a majority of revenue and has been expanding at a double-digit pace, offsetting declines in legacy products. The dividend, raised for 17 consecutive years, yields roughly 4%, supported by more than $10 billion in annual free cash flow and a $5 billion buyback program. A rich pipeline of late-stage readouts, including milvexian and Zenbexus (iberdomide), which reported positive Phase 3 data in multiple myeloma, plus reported merger discussions with AstraZeneca, provides additional optionality that some analysts argue is not fully reflected in the valuation.
The central obstacle is the patent cliff: top sellers Eliquis and Opdivo face loss of exclusivity, and analysts broadly expect revenue and earnings to decline over the next several years. U.S. drug-pricing reform, including Medicare negotiation under the Inflation Reduction Act, adds another layer of uncertainty. Sentiment has cooled recently — Wells Fargo trimmed its target to $60, Cantor Fitzgerald to $53, and Leerink Partners downgraded the stock — while Morgan Stanley's $41 target reflects a much more bearish view of the long-term earnings trajectory.
The stock sits below its 52-week high of about $68.64, which now acts as the first meaningful resistance level, with the round-number $70 mark just above it and the $73 target beyond that. On the downside, the 200-day moving average near $60 has provided support, with the $57 to $58 area representing the next level of note. A sustained move above $68.64 would break the prior high and open the path toward the $70 to $73 zone, while failure to hold $60 could signal renewed distribution.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms apply different methodologies and timeframes, which partly explains the wide $41-to-$82 spread. Investors should watch quarterly earnings and guidance updates, Eliquis and Opdivo sales trends, Medicare negotiation decisions, and late-stage data readouts for milvexian, Cobenfy, and Zenbexus. Any changes to analyst ratings or targets, particularly on the cautious side, would also matter for the stock's trajectory.
For traders seeking a more systematic view, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. These signals can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. Explore the platform to see how AI-driven signals currently read on BMY and across the broader market.
The $73 target — the average of the analyst price targets above the current price — would require a substantial gain of about 19% from recent levels near $61.48. Support comes from a fast-growing growth portfolio, a well-covered dividend, and a full pipeline of catalysts, while the patent cliff, pricing pressure, and a wave of recent target cuts argue for caution. The unusually wide $41-to-$82 range underscores genuine disagreement on Wall Street, and the $73 figure should be read as a calculated midpoint of the bullish cohort rather than a forecast. Whether BMY can reach that level will depend most on pipeline readouts and how quickly newer products can fill the revenue gap left by expiring blockbusters.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.